Kezar Life Sciences, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Marc Belsky. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Marc Belsky has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:KZR / Kezar Life Sciences, Inc. CFO 140,000
Senior Vice President and CFO 18,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Marc Belsky. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases KZR / Kezar Life Sciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in KZR / Kezar Life Sciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2020-02-04 KZR Belsky Marc 15,384 2.6000 1,538 26.0000 39,998 121 7.75 -28,078 -70.20
2019-11-13 KZR Belsky Marc 800 2.7588 80 27.5880 2,207
2019-08-20 KZR Belsky Marc 200 4.4200 20 44.2000 884
2019-08-09 KZR Belsky Marc 500 4.8200 50 48.2000 2,410
2019-07-26 KZR Belsky Marc 56 5.8000 6 58.0000 325
2019-07-25 KZR Belsky Marc 444 5.6540 44 56.5400 2,510

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KZR / Kezar Life Sciences, Inc. Insider Trades
Insider Sales KZR / Kezar Life Sciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in KZR / Kezar Life Sciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KZR / Kezar Life Sciences, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Marc Belsky as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2022-01-07 2022-01-05 4 KZR Kezar Life Sciences, Inc.
Employee Stock Option (right to buy)
A - Award 140,000 140,000
2021-01-11 2021-01-08 4 KZR Kezar Life Sciences, Inc.
Employee Stock Option (right to buy)
A - Award 220,000 220,000
2020-02-05 2020-02-04 4 KZR Kezar Life Sciences, Inc.
Common Stock
P - Purchase 15,384 15,384 2.60 39,998 39,998
2020-01-13 2020-01-12 4 KZR Kezar Life Sciences, Inc.
Employee Stock Option (right to buy)
A - Award 90,000 90,000
2019-11-13 2019-11-13 4 KZR Kezar Life Sciences, Inc.
Common Stock
P - Purchase 800 2,000 66.67 2.76 2,207 5,518
2019-09-10 2019-09-06 4 KZR Kezar Life Sciences, Inc.
Employee Stock Option (right to buy)
A - Award 60,000 60,000
2019-08-21 2019-08-20 4 KZR Kezar Life Sciences, Inc.
Common Stock
P - Purchase 200 1,200 20.00 4.42 884 5,304
2019-08-12 2019-08-09 4 KZR Kezar Life Sciences, Inc.
Common Stock
P - Purchase 500 1,000 100.00 4.82 2,410 4,820
2019-07-26 2019-07-26 4 KZR Kezar Life Sciences, Inc.
Common Stock
P - Purchase 56 500 12.61 5.80 325 2,900
2019-07-26 2019-07-25 4 KZR Kezar Life Sciences, Inc.
Common Stock
P - Purchase 444 444 5.65 2,510 2,510
2019-01-08 2019-01-06 4 KZR Kezar Life Sciences, Inc.
Employee Stock Option (right to buy)
A - Award 60,000 60,000
2018-02-28 2018-02-26 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
A - Award 18,000 18,000
2018-02-28 2018-02-26 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
A - Award 3,000 16,314 22.53
2018-02-07 2018-02-05 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
F - Taxes -1,048 13,314 -7.30 18.42 -19,304 245,244
2017-09-06 2017-09-01 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
F - Taxes -921 16,982 -5.14 34.34 -31,627 583,162
2017-03-03 2017-03-01 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
F - Taxes -18,881 46,785 -28.75 44.77 -845,302 2,094,564
2017-02-09 2017-02-07 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
A - Award 22,500 22,500
2017-02-09 2017-02-07 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
A - Award 7,031 12,656 125.00
2017-02-09 2017-02-07 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
A - Award 5,625 5,625
2017-01-05 2017-01-03 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
F - Taxes -2,281 65,666 -3.36 48.60 -110,857 3,191,368
2016-09-01 2016-09-01 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
F - Taxes 17,980 67,947 35.98 44.74 804,425 3,039,949
2016-08-29 2016-08-25 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
A - Award 30,000 30,000
2016-08-29 2016-08-25 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
A - Award 5,000 85,927 6.18
2016-04-26 2016-04-22 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
M - Exercise -3,052 41,948 -6.78
2016-04-26 2016-04-22 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
M - Exercise -12,389 17,611 -41.30
2016-04-26 2016-04-22 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
M - Exercise -11,178 5,082 -68.75
2016-04-26 2016-04-22 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
M - Exercise -7,483 509 -93.63
2016-04-26 2016-04-22 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
S - Sale X -33,002 80,927 -28.97 50.03 -1,651,090 4,048,778
2016-04-26 2016-04-22 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
S - Sale X -1,100 113,929 -0.96 49.24 -54,164 5,609,864
2016-04-26 2016-04-22 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
M - Exercise 3,052 115,029 2.73 19.25 58,751 2,214,308
2016-04-26 2016-04-22 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
M - Exercise 12,389 111,977 12.44 11.14 138,013 1,247,424
2016-04-26 2016-04-22 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
M - Exercise 11,178 99,588 12.64 7.26 81,152 723,009
2016-04-26 2016-04-22 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
M - Exercise 7,483 88,410 9.25 5.54 41,456 489,791
2016-04-08 2016-04-06 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
M - Exercise -138 7,992 -1.70
2016-04-08 2016-04-06 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
M - Exercise -8,943 0 -100.00
2016-04-08 2016-04-06 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
M - Exercise -11,382 0 -100.00
2016-04-08 2016-04-06 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
M - Exercise -351 0 -100.00
2016-04-08 2016-04-06 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
S - Sale X -20,814 80,927 -20.46 45.04 -937,463 3,644,952
2016-04-08 2016-04-06 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
M - Exercise 138 101,741 0.14 5.54 765 563,645
2016-04-08 2016-04-06 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
M - Exercise 8,943 101,603 9.65 8.49 75,926 862,609
2016-04-08 2016-04-06 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
M - Exercise 11,382 92,660 14.00 6.89 78,422 638,427
2016-04-08 2016-04-06 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
M - Exercise 351 81,278 0.43 4.56 1,601 370,628
2016-03-31 2016-03-30 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
M - Exercise -9,052 351 -96.27
2016-03-31 2016-03-30 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
S - Sale X -9,052 80,927 -10.06 40.01 -362,171 3,237,889
2016-03-31 2016-03-30 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
M - Exercise 9,052 89,979 11.19 4.56 41,277 410,304
2016-03-31 2016-03-29 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
M - Exercise -4,824 9,403 -33.91
2016-03-31 2016-03-29 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
S - Sale X -4,824 80,927 -5.63 40.00 -192,960 3,237,080
2016-03-31 2016-03-29 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
M - Exercise 4,824 85,751 5.96 4.56 21,997 391,025
2015-08-21 2015-08-20 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
A - Award 75,000 80,680 1,320.42
2015-08-19 2015-08-17 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
A - Award 45,000 45,000
2015-05-04 2015-04-30 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
A - Award 5,680 5,680
2014-08-26 2014-08-22 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
A - Award 30,000 30,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)